Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Polymerized grass pollen extract** is a chemically modified allergen extract used for subcutaneous immunotherapy (SCIT) in patients with grass pollen-induced allergic rhinoconjunctivitis. It consists of a standardized mixture of six grasses (Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior) and rye pollen (Secale cereale), treated with glutardialdehyde to polymerize the allergens, reducing IgE reactivity and enabling rapid cluster up-dosing schedules. Adsorbed onto aluminum hydroxide, it is administered subcutaneously, achieving maintenance doses (e.g., 5000 TU) quickly, with demonstrated efficacy in reducing symptom and medication scores by 36-43% in phase III trials, alongside immunological effects like increased specific IgG4.[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polymerized grass pollen extract.